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A B S T R A C T
Background
The treatment of people with pancreatic necrosis differs from that of people with oedematous pancreatitis. It is important to know the
diagnostic accuracy of serum C-reactive protein (CRP), serum procalcitonin, and serum lactate dehydrogenase (LDH) as a triage test
for the detection of pancreatic necrosis in people with acute pancreatitis, so that an informed decision can be made as to whether the
person with pancreatic necrosis needs further investigations such as computed tomography (CT) scan or magnetic resonance imaging
(MRI) scan and treatment for pancreatic necrosis started. There is currently no standard clinical practice, although CRP, particularly an
increasing trend of CRP, is often used as a triage test to determine whether the person requires further imaging. There is also currently
no systematic review of the diagnostic test accuracy of CRP, procalcitonin, and LDH for the diagnosis of pancreatic necrosis in people
with acute pancreatitis.
Objectives
To compare the diagnostic accuracy of CRP, procalcitonin, or LDH (index test), either alone or in combination, in the diagnosis of
necrotising pancreatitis in people with acute pancreatitis and without organ failure.
Search methods
We searchedMEDLINE, Embase, Science Citation Index Expanded, National Institute for Health Research (NIHRHTA and DARE),
and other databases until March 2017. We searched the references of the included studies to identify additional studies. We did
not restrict studies based on language or publication status, or whether data were collected prospectively or retrospectively. We also
performed a ’related search’ and ’citing reference’ search in MEDLINE and Embase.
Selection criteria
We included all studies that evaluated the diagnostic test accuracy of CRP, procalcitonin, and LDH for the diagnosis of pancreatic
necrosis in people with acute pancreatitis using the following reference standards, either alone or in combination: radiological features
of pancreatic necrosis (contrast-enhanced CT or MRI), surgeon’s judgement of pancreatic necrosis during surgery, or histological
confirmation of pancreatic necrosis. Had we found case-control studies, we planned to exclude them because they are prone to bias;
however, we did not locate any. Two review authors independently identified the relevant studies from the retrieved references.
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Data collection and analysis
Two review authors independently extracted data, including methodological quality assessment, from the included studies. As the
included studies reported CRP, procalcitonin, and LDH on different days of admission and measured at different cut-off levels, it was
not possible to perform a meta-analysis using the bivariate model as planned. We have reported the sensitivity, specificity, post-test
probability of a positive and negative index test along with 95% confidence interval (CI) on each of the different days of admission
and measured at different cut-off levels.
Main results
A total of three studies including 242 participants met the inclusion criteria for this review. One study reported the diagnostic
performance of CRP for two threshold levels (> 200 mg/L and > 279 mg/L) without stating the day on which the CRP was measured.
One study reported the diagnostic performance of procalcitonin on day 1 (1 day after admission) using a threshold level of 0.5 ng/mL.
One study reported the diagnostic performance of CRP on day 3 (3 days after admission) using a threshold level of 140 mg/L and LDH
on day 5 (5 days after admission) using a threshold level of 290 U/L. The sensitivities and specificities varied: the point estimate of
the sensitivities ranged from 0.72 to 0.88, while the point estimate of the specificities ranged from 0.75 to 1.00 for the different index
tests on different days of hospital admission. However, the confidence intervals were wide: confidence intervals of sensitivities ranged
from 0.51 to 0.97, while those of specificities ranged from 0.18 to 1.00 for the different tests on different days of hospital admission.
Overall, none of the tests assessed in this review were sufficiently accurate to suggest that they could be useful in clinical practice.
Authors’ conclusions
The paucity of data and methodological deficiencies in the studies meant that it was not possible to arrive at any conclusions regarding
the diagnostic test accuracy of the index test because of the uncertainty of the results. Further well-designed diagnostic test accuracy
studies with prespecified index test thresholds of CRP, procalcitonin, LDH; appropriate follow-up (for at least two weeks to ensure
that the person does not have pancreatic necrosis, as early scans may not indicate pancreatic necrosis); and clearly defined reference
standards (of surgical or radiological confirmation of pancreatic necrosis) are important to reliably determine the diagnostic accuracy
of CRP, procalcitonin, and LDH.
P L A I N L A N G U A G E S U M M A R Y
Blood tests for the diagnosis of pancreatic necrosis (pancreatic destruction due to inflammation of pancreas)
Background
The pancreas is an organ in the abdomen (tummy) that secretes several digestive enzymes (substances that break down the food that
we eat) into the pancreatic ductal system, which empties into the small bowel. The pancreas also contains the islets of Langerhans,
which secrete several hormones including insulin (which helps regulate blood sugar). Acute pancreatitis is a sudden inflammation of
the pancreas that can lead to destruction of the pancreas (pancreatic necrosis). The treatment of people with pancreatic necrosis differs
from that of people without pancreatic necrosis. Blood tests such as C-reactive protein (CRP), procalcitonin, and lactate dehydrogenase
(LDH) may be used to find out whether a person with acute pancreatitis has pancreatic necrosis. This is usually followed by CT scan
to confirm that the person has pancreatic necrosis. If the person is found to have pancreatic necrosis, the intensity of care is increased
and additional treatments are performed as required. At present it is unclear whether measuring the levels of CRP, procalcitonin, or
LDH is useful in identifying pancreatic necrosis.
Study characteristics
We performed a thorough literature search for studies reporting the accuracy of CRP, procalcitonin, or LDH in identifying pancreatic
necrosis. We included studies reported until 20 March 2017. We identified three studies reporting information on 242 people with
pancreatitis. The studies included pancreatitis due to all causes.
Key results
Variations in when the studies carried out the blood tests and what level was considered abnormal meant that we were unable to
combine the data to provide the overall results. It was not possible to arrive at any firm conclusions about how accurate the tests are for
the following reasons.
• The studies included few participants. As a result, there was significant uncertainty in the results.
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• The studies were of poor methodological quality, which introduced additional uncertainty in the results.
• For the results to be trusted, they must be reproduced in another group of participants. Since this was not done, there was uncertainty
in the results.
Quality of evidence
All of the studies were of unclear or low methodological quality, which may result in arriving at false conclusions.
B A C K G R O U N D
(See Appendix 1 for a glossary of terms.)
The pancreas is an abdominal organ that secretes several digestive
enzymes into the pancreatic ductal system, which empties into
the small bowel. It also contains the islets of Langerhans, which
secrete several hormones, including insulin (NCBI 2014a). Acute
pancreatitis is a sudden inflammatory process in the pancreas, with
variable involvement of adjacent organs or other organ systems
(Bradley 1993). The annual incidence of acute pancreatitis ranges
from 5 to 30 per 100,000 population (Roberts 2013; Yadav 2006).
In the last one to two decades there has been an increase in the
incidence of acute pancreatitis in the UK and the USA (Roberts
2013; Yang 2008). Acute pancreatitis is the most common gas-
trointestinal (digestive tract) cause of hospital admission in the
USA (Peery 2012). Gallstones and alcohol are the twomain causes
of acute pancreatitis. Approximately 50% to 70% of acute pancre-
atitis cases are caused by gallstones (Roberts 2013; Yadav 2006).
Increasing age, male gender, and lower socioeconomic class are
associated with a higher incidence of acute pancreatitis (Roberts
2013).
According to a consensus conference on the classification of acute
pancreatitis, the diagnosis of acute pancreatitis is generally made
when at least two of the following three features are present (Banks
2013).
1. Acute onset of a persistent, severe epigastric pain often
radiating to the back.
2. Serum lipase activity (or amylase activity) at least three
times greater than the upper limit of normal.
3. Characteristic findings of acute pancreatitis on contrast-
enhanced computed tomography (CECT) and, less commonly,
magnetic resonance imaging (MRI) or transabdominal
ultrasonography.
Acute pancreatitis can be classified into interstitial oedematous
pancreatitis (diffuse or occasionally localised enlargement of the
pancreas due to inflammatory oedema as seen onCECT) or necro-
tising pancreatitis (necrosis involving either the pancreas or peri-
pancreatic tissues or both) (Banks 2013). Approximately 90% to
95% of people with acute pancreatitis have interstitial oedema-
tous pancreatitis, while the remainder have necrotising pancreati-
tis (Banks 2013). Necrotising pancreatitis may be sterile or in-
fected (Banks 2013). Various theories exist as to how pancreatic
and peripancreatic tissues become infected. These include spread
from blood circulation, lymphatics, bile, from the small bowel
(duodenum) through the pancreatic duct, and migration through
the large bowel wall (translocation) (Schmid 1999).
Local complications of acute pancreatitis include acute peripan-
creatic fluid collection, pancreatic pseudocyst, acute necrotic col-
lection, and walled-off necrosis (Banks 2013). Systemic compli-
cations of acute pancreatitis include worsening of pre-existing ill-
nesses, such as heart or chronic lung disease (Banks 2013). The
mortality rate following an attack of acute pancreatitis is between
6% and 20% (Roberts 2013; Yadav 2006), and depends upon the
severity of the acute pancreatitis and the presence of infection.
Acute pancreatitis can be classified as mild, moderate, or severe
depending upon the presence of local or systemic complications,
transient organ failure involving one of more of lungs, kidneys,
and cardiovascular system (heart and blood vessels) lasting up to
48 hours, or persistent failure of the same organsmentioned above,
lasting beyond 48 hours. In mild pancreatitis, there are no local
or systemic complications, or organ failure. In moderately severe
acute pancreatitis, theremay be local or systemic complications, or
transient organ failure. In severe acute pancreatitis, there is persis-
tent organ failure (Banks 2013). (See summary in Table 1.) Acute
severe pancreatitis carries the worst prognosis in terms ofmortality,
while mild pancreatitis has the best prognosis (Banks 2013). In-
fected necrotising pancreatitis carries a significantly worse progno-
sis than sterile necrotising pancreatitis, with an average in-hospital
mortality of more than 30% for people with infected necrotising
pancreatitis, which increases to more than 40% in the subgroup of
people with organ failure in addition to infection (Petrov 2010).
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Target condition being diagnosed
Acute necrotising pancreatitis in people with an established diag-
nosis of acute pancreatitis.
Index test(s)
All of the index tests evaluated in this review are performed by the
laboratory technician and interpreted by the clinician.
Diagnosis of necrotising pancreatitis in people with an
established diagnosis of acute pancreatitis
Serum C-reactive protein (CRP)
C-reactive protein is a plasma protein that increases during inflam-
mation and after tissue damage (NCBI 2014b). Inflammation and
tissue damage occur in people with pancreatic necrosis. However,
activation of inflammatory pathways is considered to be one of the
reasons for the clinical manifestation of acute pancreatitis (Banks
2013), and hence serum CRP can be elevated even in oedematous
pancreatitis. One of the thresholds proposed for distinguishing
oedematous pancreatitis and necrotising pancreatitis is 140 mg/L
(Rau 1998). An increasing trend in the values of the test may also
be used for the triage of people who require radiological examina-
tion.
Serum procalcitonin
Procalcitonin is the precursor of the hormone calcitonin found in
the thyroidCcells and the pulmonary endocrine cells.However, all
tissues have the potential to produce procalcitonin. In people with
sepsis and severe inflammation, procalcitonin is elevated (Becker
2010). Since pancreatic necrosis is associated with severe inflam-
mation, serum procalcitonin may distinguish between oedema-
tous pancreatitis and necrotising pancreatitis. Procalcitonin levels
are undetectable in healthy adults. Hence, any detectable levels
of serum procalcitonin can be considered to be abnormal. An in-
creasing trend in the values of the test may also be used for the
triage of people who require radiological examination.
Serum lactate dehydrogenase (LDH)
Lactate dehydrogenase is an indicator of cell death. Since pancre-
atic necrosis is associated with cell death, LDH may distinguish
between oedematous pancreatitis and pancreatic necrosis. Normal
LDH levels range from 140 units/L to 280 units/L. One of the
thresholds proposed for distinguishing oedematous pancreatitis
and necrotising pancreatitis is 290 units/L (Rau 1998). An in-
creasing trend in the values of the test may also be used for the
triage of people who require radiological examination.
Clinical pathway
For people with acute onset of a persistent, severe, epigastric pain
or people with diffuse abdominal pain that started in the epigastric
region (or if the person is unsure about the region in which diffuse
abdominal pain began), clinical examination including recording
of blood pressure, pulse rate, and oxygen saturations (when avail-
able) are performed. Routine blood tests such as full blood count,
urea, creatinine, and electrolytes are also performed. Blood tests
such as amylase and lipase are performed to confirm (or rule out)
the diagnosis of acute pancreatitis. Radiological findings of acute
pancreatitis evolve over a few days, and the radiological features
may not be apparent in the early stages, or may even be normal
(Banks 2013; Vissers 1999); thus, one cannot rely on radiological
tests to diagnose acute pancreatitis, at least in the early stages. Ra-
diological examination with computed tomography (CT scan) or
MRI scan is not routinely performed if a diagnosis of acute pan-
creatitis is suspected. If acute pancreatitis can be ruled out, other
causes of acute epigastric pain should be considered. Peptic ulcer,
functional dyspepsia, and gallstones can present with acute epigas-
tric pain (Gurusamy 2014; Moayyedi 2006). All of these alterna-
tive causes of epigastric pain are generally investigated and treated
after discharge of the person unless there is a strong suspicion of
perforated peptic ulcer, usually because of features of peritonitis
or because pain control could not be achieved. In such instances,
either a plain X-ray of the abdomen or emergency CT scan, or
both may be performed to identify the presence of free-intraperi-
toneal gas (Ghekiere 2007; Grassi 2004). The usual treatment for
perforated peptic ulcer is emergency surgical closure, which can
be performed by open or laparoscopic surgery (Sanabria 2013).
If a diagnosis of acute pancreatitis can be established, usually based
on the consensus criteria, the person is admitted to hospital and
the severity of pancreatitis assessed. The treatment of acute pan-
creatitis is generally supportive treatment, that is maintenance of
fluid and electrolyte imbalance. Despite various pharmacologi-
cal interventions being evaluated in acute pancreatitis, none is
currently recommended as treatment. Abdominal ultrasound and
magnetic resonance cholangiopancreatography or endoscopic ul-
trasound may be performed to investigate the aetiology of acute
pancreatitis. In the presence of gallstones, cholecystectomy is per-
formed. The timing of cholecystectomy in acute pancreatitis is
controversial, and different factors must be considered depending
upon the severity of the acute pancreatitis (Gurusamy 2013). En-
doscopic sphincterotomy or common bile duct exploration may
need to be performed in the presence of common bile duct stones
(Ayub 2004; Larson 2006). In the absence of gallstones, investi-
gation of other causes of acute pancreatitis is required. People are
generally monitored clinically. If the person improves clinically
with supportive treatment, the person with gallstone pancreatitis
is discharged after cholecystectomy or after scheduling a chole-
cystectomy or on a planned list, within the two weeks. For those
people with severe acute pancreatitis, cholecystectomy is under-
taken when clinically appropriate after resolution of pancreatitis
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(NCEPOD 2016). If the person deteriorates clinically, the per-
son undergoes a CT scan and may require high-dependency or
intensive care unit care in the presence of organ failure or in the
presence of infected pancreatic necrosis.
In the presence of organ failure, the person undergoes a CT scan
or MRI to identify any local complications. C-reactive protein,
procalcitonin, and LDH might distinguish between oedematous
and necrotising pancreatitis (Alfonso 2003; Khanna 2013; Rau
1998), and could potentially be used as a triage test to iden-
tify who among those without organ failure needs further radi-
ological tests (Alfonso 2003). Some centres use CRP routinely
to determine whether people require radiological investigations
to diagnose necrotising pancreatitis. Frequently, a rising trend in
CRP, procalcitonin, or LDH rather than a single test may be used
to determine whether people require radiological investigations
to diagnose necrotising pancreatitis. It should be noted that CT
scan or MRI is not routinely performed during the initial stages
of acute pancreatitis but usually in the presence of organ fail-
ure or due to the results of the serum CRP. The various treat-
ment strategies in acute necrotising pancreatitis include non-sur-
gical (conservative) treatment, percutaneous drainage, endoscopic
transluminal drainage, early surgical debridement (necrosectomy,
which can be performed by open surgery or by minimally inva-
sive retroperitoneal debridement), delayed necrosectomy (delay-
ing the surgery by about four weeks), or a step-up approach that
consists of endoscopic or percutaneous drainage followed by la-
paroscopic necrosectomy if required, and non-surgical (conser-
vative) treatment (Bakker 2012; Mouli 2013; Tenner 2013; van
Brunschot 2014; van Santvoort 2010; van Santvoort 2011). A re-
cent Cochrane systematic review found that a step-up approach
may be preferable to direct surgery in people with acute necrotis-
ing pancreatitis (Gurusamy 2016). All of these treatments are sup-
ported by appropriate fluid therapy and nutritional support. This
is in comparison with severe acute oedematous pancreatitis, where
the main treatment is supportive treatment for systemic compli-
cations including organ failure and treatment of local complica-
tions such as pseudocyst if symptomatic (Cannon 2009; Cheruvu
2003; Johnson 2009; Varadarajulu 2008; Varadarajulu 2013). In
the case of infected pancreatic necrosis, appropriate antibiotics are
administered in addition to the treatment outlined above for non-
infected pancreatic necrosis. In the case of acute peripancreatic
collections or pseudocysts on the radiological tests, the person re-
quires clinical and radiological follow-up to ensure resolution of
these collections.
If the diagnosis of acute pancreatitis cannot be ruled out on the
basis of the clinical presentation and serum amylase or lipase, the
person is admitted to hospital and the evolution of signs and symp-
toms is noted. Serum amylase and lipase may be repeated, or ra-
diological examinations may be performed to establish or rule out
acute pancreatitis with a reasonable amount of certainty. Tests for
organ failure (e.g. urea and creatinine for identifying renal failure,
blood pressure, pulse rate, respiratory rate, urine output, and ar-
terial blood gases) may also be performed to ensure that moder-
ately severe or severe pancreatitis is not present irrespective of the
results of serum amylase and lipase. The possible clinical pathway
in the diagnosis and management of acute pancreatitis is shown
in Figure 1.
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Figure 1. Clinical pathway.Footnotes:Acute pancreatitis is usually confirmed by consensus criteria (Banks
2013).Irrespective of the CT scan findings and presence or absence of necrosis, people with organ failure will
require organ support and will receive a CT scan.CT scan may also be performed in people without organ
failure if there is clinical deterioration (not amounting to organ failure) or in some centres based on an
elevated CRP.Necrotising pancreatitis is usually confirmed by the findings on the CT scan and by
histopathological examination of the biopsy obtained during necrosectomy if early necrosectomy is
performed.Infected necrotising pancreatitis is usually confirmed by the findings on the CT scan and by
microbiological examination of fluid aspirated under radiological guidance or from the tissue biopsy obtained
during necrosectomy if early necrosectomy is performed.Organ failure is diagnosed on the basis of clinical
examination and blood tests (urea, creatinine, blood pressure, pulse rate, respiratory rate, arterial blood gas
analysis).Abbreviations:CRP: C-reactive proteinCT: computed tomographyEUS: endoscopic ultrasoundMRCP:
magnetic resonance cholangiopancreatography
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Prior test(s)
The tests that are performedbefore the index tests, such as serum li-
pase or amylase, are used to establish the diagnosis of acute pancre-
atitis. If necessary, these are supported with radiological tests such
as CECT, MRI, or transabdominal ultrasonography, and clinical
examination and blood tests to rule out organ failure (e.g. urea and
creatinine for identifying renal failure, blood pressure, pulse rate,
respiratory rate, urine output, and arterial blood gases). Of these
tests, serum tests for the diagnosis of acute pancreatitis, clinical
examination, and blood tests to rule out organ failure are routinely
performed, while CT scan is performed if there is uncertainty in
the diagnosis of acute pancreatitis. The minimum prior tests are
thus serum lipase, serum amylase, clinical examination, and blood
tests to rule out organ failure.
Role of index test(s)
Currently, if necrotising pancreatitis is suspected in people without
organ failure, radiological investigations are performed directly, al-
though some units may use CRP (in particular an increasing trend
in CRP values) to identify those who require radiological inves-
tigations. In people where the diagnosis of acute pancreatitis was
based on CT scan, it is quite possible that the radiological features
of necrosis are not manifest initially, as there may be a delay in
their appearance (Banks 2013). In such cases, CRPmay be used to
identify people who require additional radiological investigations.
We evaluated the index tests (CRP, procalcitonin, and LDH) as
triage tests for detecting pancreatic necrosis in people with acute
pancreatitis in whom the diagnosis of pancreatic necrosis has not
been made. Further radiological tests such as CECT will be nec-
essary for confirming pancreatic necrosis, and the location and ex-
tent of pancreatic necrosis, before treatment can be planned. We
did not evaluate the role of these tests in monitoring necrotising
pancreatitis once the diagnosis of necrotising pancreatitis is made.
Alternative test(s)
Other tests used in the diagnosis of pancreatic necrosis include
CECT, MRI, or transabdominal ultrasonography (Banks 2013).
Various other blood tests such as blood haematocrit, blood urea,
serum creatinine, and procarboxypeptidase B have been evaluated
as diagnostic tests for pancreatic necrosis, but these are not in
routine use for the diagnosis of pancreatic necrosis (Muddana
2009; Rau 1998).
Rationale
The treatment of people with acute pancreatitis differs between
people with and those without pancreatic necrosis, as mentioned
in the clinical pathway (Figure 1). People with organ failure rou-
tinely undergo radiological investigations, while those without or-
gan failure do not routinely undergo CT scans. Some units already
use CRP as a triage test to identify people without organ failure
who require radiological investigations and admission to high de-
pendency unit or intensive therapy unit, while others do not. The
role of CRP, procalcitonin, and LDH as triage tests is thus unclear.
There is no current systematic review of the diagnostic test accu-
racy of CRP, procalcitonin, or LDH in the diagnosis of pancreatic
necrosis. A Cochrane systematic review of the diagnostic test accu-
racy of CRP, procalcitonin, or LDH in the diagnosis of pancreatic
necrosis was needed to understand the value of these tests as triage
tests to identify people who require radiological investigation.
O B J E C T I V E S
To compare the diagnostic accuracy of CRP, procalcitonin, or
LDH, either alone or in combination, in the diagnosis of necro-
tising pancreatitis in people with acute pancreatitis and without
organ failure.
Secondary objectives
We planned to explore the following sources of heterogeneity.
• Studies at low risk of bias versus those at unclear or high
risk of bias (as assessed by the Quality Assessment of Diagnostic
Accuracy Studies (QUADAS-2) tool, recommended by the
Cochrane Diagnostic Test Accuracy Group) (Whiting 2006;
Whiting 2011).
• Prospective studies versus retrospective studies (to
determine whether there is a difference in diagnostic accuracy
between prospective and retrospective studies).
• Full-text publications versus abstracts (this can be indicative
of publication bias, since there may be an association between
the results of the study and the study reaching full publication
status) (Eloubeidi 2001).
• Previous history of acute pancreatitis.
• Different aetiology for acute pancreatitis (gallstone versus
alcohol versus other aetiology). The accuracy of the test may
depend upon the aetiology of the acute pancreatitis.
• Presence or absence of infection. The accuracy of the test
may depend upon the presence or absence of infection.
• Pancreatic versus peripancreatic necrosis.
• Average time to performance of the test. The accuracy of
the test may depend upon the interval between the onset of
clinical symptoms and the performance of the test.
• Different test manufacturers.
7Serum C-reactive protein, procalcitonin, and lactate dehydrogenase for the diagnosis of pancreatic necrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included studies that evaluated the accuracy of the index tests
mentioned above in the appropriate population (see below). We
included relevant studies irrespective of language or publication
status; whether the data were collected prospectively or retrospec-
tively; and whether there was a comparison between the tests.
However, we excluded case reports (which describe how the di-
agnosis of acute pancreatitis or acute necrotising pancreatitis was
made on an individual participant or a group of participants and
which do not provide sufficient diagnostic test accuracy data, i.e.
true positive, false positive, false negative, and true negative). We
also planned to exclude case-control studies because they are prone
to bias (Whiting 2011); however, we did not identify any case-
control studies.
Participants
Adult participants with acute pancreatitis within 14 days of the
onset of symptoms (irrespective of the interval between the onset
of symptoms and the time at which the test was performed). The
diagnosis of acute pancreatitis should have been made on the basis
of the consensus conference definition (Banks 2013). Participants
who had already developed organ failure at the time of perform-
ing these tests were excluded, since all such participants undergo
radiological investigations. Although we had planned to exclude
participants in whom pancreatic necrosis was present on the CT
scan used to diagnose acute pancreatitis, this information was not
available from the studies.
Index tests
Serum CRP, procalcitonin, and LDH either alone or in combi-
nation immediately prior to radiological investigation. A variety
of kits are available for measuring these tests. We included kits
from all manufacturers, and included studies irrespective of the
threshold used. We included studies that reported a single test and
sequential tests of serum CRP, procalcitonin, and LDH. If the
study reported sequential testing, we planned to consider a pro-
gressive increase as a positive index test irrespective of the degree
of increase, and stationary or decrease in the levels as a negative
test; however, none of the studies reported this information de-
spite measuring the levels on different days.
Target conditions
Pancreatic necrosis (i.e. infected or sterile pancreatic or peripan-
creatic necrosis)
Reference standards
While considered to be the gold standard for confirming necrosis,
biopsy may not have been performed in all participants due to
ethical concerns over performing an invasive treatment (during
which biopsy is taken) in those without a diagnosis of pancreatic
necrosis. As a result, study authors may use radiological features
of pancreatic necrosis (an area of reduced enhancement or non-
enhancing area of pancreatic parenchyma on CECT or contrast-
enhanced MRI). However, this reference standard may miss some
cases of pancreatic necrosis, resulting in underestimation of diag-
nostic test accuracy of the index tests. In addition, using radiolog-
ical features of pancreatitis might introduce an intrinsic thresh-
old effect because of interobserver variation between radiologists.
As per protocol, we accepted any of the following reference stan-
dards, used alone or in combination: radiological features of pan-
creatic necrosis (CECT or contrast-enhanced MRI) or histologi-
cal confirmation of pancreatic necrosis. We also included a com-
bination of radiological features of pancreatic necrosis (CECT or
contrast-enhanced MRI) and surgeon’s judgement of pancreatic
necrosis during surgery, as we considered this equivalent to radiol-
ogist judgement of the presence of pancreatic necrosis on CECT
or contrast-enhanced MRI. In terms of ranking the reference stan-
dards, we considered biopsy in all participants as the best reference
standard (although it is unlikely to be performed in participants
with a negative test for pancreatic necrosis) followed by biopsy in
participants with positive test and radiological or surgical features
of pancreatic necrosis in participants with negative test, and ra-
diological tests or surgery alone as the reference standard, in that
order.
Search methods for identification of studies
We included all studies irrespective of the language of publication
and publication status. We translated non-English language arti-
cles.
Electronic searches
We searched the following databases.
1. MEDLINE (In-Process & Other Non-Indexed Citations
and Ovid MEDLINE(R)) via OvidSP (January 1946 to 20
March 2017) (Appendix 2).
2. Embase via OvidSP (January 1947 to 20 March 2017)
(Appendix 3).
3. Science Citation Index Expanded via Web of Knowledge
(January 1980 to 20 March 2017) (Appendix 4).
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4. Conference Proceedings Citation Index-Science (CPCI-S)
via Web of Knowledge (January 1990 to 20 March 2017)
(Appendix 4)
5. National Insitute for Health Research (NIHR HTA and
DARE) via Centre for Reviews and Dissemination (20 March
2017) (Appendix 5).
6. Zetoc via British Library (20 March 2017) (Appendix 6).
7. World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (www.who.int/ictrp/en/) (20
March 2017) (Appendix 7).
8. ClinicalTrials.gov (clinicaltrials.gov/) (20 March 2017)
(Appendix 8).
We used this same strategy in another review on diagnosis of acute
pancreatitis in people with acute epigastric or diffuse abdominal
pain (Gurusamy 2015).
Searching other resources
We searched the references of the included studies to identify addi-
tional studies. We also searched for articles related to the included
studies by performing the ’related search’ function in MEDLINE
(OvidSP) and Embase (OvidSP) and a ’citing reference’ search
(by searching the articles that cite the included articles) in these
databases (Sampson 2008).
Data collection and analysis
Selection of studies
Two review authors (OK and KSG) independently identified rel-
evant studies from the retrieved references. We obtained the full
texts of references considered to be relevant by at least one of the
review authors. Two review authors independently screened the
full-text papers against the inclusion criteria and resolved any dif-
ferences through discussion. We planned to contact the study au-
thors if there were any doubts about study eligibility.
Data extraction and management
Two review authors (OK and KSG) independently extracted the
following data from each included study using a data extraction
form designed and piloted by KSG, resolving any differences by
discussion.
• First author.
• Year of publication.
• Study design (prospective or retrospective cohort studies;
cross-sectional studies or randomised comparisons of index tests).
• Inclusion and exclusion criteria for individual studies.
• Total number of participants.
• Number of females.
• Average age of the participants.
• Average time between onset of symptoms and index test.
• Aetiology of acute pancreatitis.
• Proportion of participants with infected pancreatic necrosis.
• Description of the index test.
• Threshold used for the index test.
• Reference standard.
• Information to complete the QUADAS-2 assessment
(please see below).
• Number of true positives, false positives, false negatives,
and true negatives.
If the same study reported multiple index tests, we extracted the
number of true positives, false positives, false negatives, and true
negatives for each index test. If the same study reported the num-
ber of true positives, false positives, false negatives, and true neg-
atives for each index test at different thresholds, we extracted this
information for each threshold. If the study reported the results
for a combination of tests, we planned to extract the number of
true positives, false positives, false negatives, and true negatives for
each different combination of tests; however, we did not find any
such studies.
A common way that the diagnostic accuracy of a combination
of tests is assessed is at least one test positive versus all tests pos-
itive. We planned to extract the number of true positives, false
positives, false negatives, and true negatives for both the scenarios
(at least one test positive and all tests positive). If the study re-
ported the test at multiple time points, we planned to obtain the
trend in sequential testing of CRP, procalcitonin, or LDH if the
author used a progressively increasing trend in index test values
for distinguishing acute necrotising pancreatitis and oedematous
pancreatitis. For this purpose, we planned to consider an increas-
ing trend as a positive index test irrespective of the degree of in-
crease, and consider stationary levels or a decrease in the levels as
a negative test in order to calculate the number of true positives,
false positives, false negatives, and true negatives. If the authors
provided the final values of these index tests prior to radiological
examination, we planned to obtain these values for calculating the
true positives, false positives, false negatives, and true negatives.
We did this because we wanted to evaluate the role of these index
tests used as a test with a prespecified threshold, and the role of an
increasing trend in the values of these index tests for distinguishing
acute necrotising pancreatitis and oedematous pancreatitis. The
rationale for using the final values to calculate the diagnostic test
accuracy is as follows. Participants may receive treatment for organ
failure if they developed organ failure between the index test and
reference standard.We anticipated that a radiological investigation
would have been performed within 24 hours of diagnosis of organ
failure. Pancreatic necrosis does not resolve in 24 hours, and there
will be no alteration of the final diagnosis by the treatment in par-
ticipants with pancreatic necrosis. People with oedematous pan-
creatitis and organ failure may develop pancreatic necrosis in the
absence of appropriate treatment. Consequently, there is a possible
interaction between inadequate treatment and the final diagnosis.
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The final values, which have the shortest time interval between
the index test and reference standard, are the least likely to be af-
fected by inappropriate treatment and are likely to provide the best
estimates of diagnostic test accuracy. Although studies measured
the index tests at several time points, the diagnostic test accuracy
results were provided only at a specific time point, therefore we
did not use trend in values as a threshold in this review.
We excluded participants with uninterpretable index test results
(irrespective of the reason given for lack of interpretation) from
the diagnostic test accuracy data since in clinical practice, uninter-
pretable index test results would result in additional tests for the
diagnosis of acute pancreatitis. However, we recorded the number
of uninterpretable index test results in a separate data column, as
this would provide information on the applicability of the test in
clinical practice (i.e. the number of individuals in whom the test
provides interpretable results) andmay affect the cost-effectiveness
of a test. Although cost-effectiveness is outside the scope of this
review, cost-effectiveness studies may use data from this review. If
there was an overlap of participants between multiple reports, as
suggested by common authors and centres, we planned to contact
the study authors to seek clarification about the overlap. If we were
unable to contact the authors, we planned to extract themaximum
possible information from all of the reports. However, we did not
find any such reports. We attempted to contact the study authors
for further information where necessary.
Assessment of methodological quality
Two review authors (OK and KSG) independently assessed study
quality using the QUADAS-2 assessment tool (Whiting 2006;
Whiting 2011). Any differences were resolved by discussion using
the QUADAS-2 table from the protocol shown in Table 2. We
considered studies classified as ’low risk of bias’ and ’low concern’ in
all of the domains (except for the reference standard domain,where
we accepted a ’No’ for the signalling question ’Is the reference
standard likely to correctly classify the target condition?’) as studies
with high methodological quality, that is we accepted a study to
be of high methodological quality despite not using histological
confirmation of pancreatic necrosis (as it is unethical to perform a
biopsy in a person with a low likelihood of not having pancreatic
necrosis), provided that it was classified as at low risk of bias for all
other domains and low concern in all domains. We have presented
the results in a ’Risk of bias’ summary and graphs in addition to a
narrative summary.
Statistical analysis and data synthesis
We stratified the analysis by the test thresholds (i.e. tests at different
thresholds were considered as different index tests) and planned
to stratify the analysis by different reference standards (if the same
test was assessed in different studies using different reference stan-
dards, it was considered as different index tests). If the study used
increasing trend in the values of CRP, procalcitonin, or LDH as
the diagnostic criteria for distinguishing necrotising pancreatitis
from oedematous pancreatitis, we planned to consider this as the
’threshold’ for the purpose of this review. We plotted study esti-
mates of sensitivity and specificity on forest plots and in receiver
operating characteristic (ROC) space to explore between-study
variation in the performance of each test stratified by the thresh-
old and reference standard. To estimate the summary sensitivity
and specificity of each test at each threshold level and each refer-
ence standard, we planned to perform the meta-analysis by fitting
the bivariate model (Chu 2006; Reitsma 2005). This model ac-
counts for between-study variability in estimates of sensitivity and
specificity through the inclusion of random effects for the logit
sensitivity and logit specificity parameters of the bivariate model.
If sparse data resulted in unreliable estimation of the covariance
matrix of the random effects as indicated by very large variance of
logit sensitivity and specificity, we planned to perform the analysis
using simplermodels suggested by Takwoingi 2015 and colleagues
using the distribution of sensitivities and specificities as noted in
the forest plots or ROC space and -2 log likelihood to choose the
model.
We planned to compare the diagnostic accuracy of the different
tests by including a single covariate term for test type in the bi-
variate model to estimate differences in the sensitivity and speci-
ficity of the tests. We planned to consider a combination of tests
for each of the scenarios (any test positive or all tests positive)
as different index tests. We planned to allow the variances of the
random effects and their covariance to also depend on test type,
thus allowing the variances to differ between tests. We planned
to use the hierarchical summary receiver operating characteristics
curve (HSROC) to test hypotheses about whether one test is su-
perior to another and to investigate heterogeneity (Rutter 2001).
For this purpose, we planned to combine tests irrespective of the
thresholds and reference standards, as we expected few studies at
each threshold level and reference standard. In case the study re-
ported results at multiple thresholds, we planned to employ the
threshold used for primary analysis by the authors for inclusion
in the HSROC model. We planned to use likelihood ratio tests
to compare the model with and without covariate (test type). A
P value of less than 0.05 for the likelihood ratio test would have
indicated differences in diagnostic accuracy between the tests. We
also planned to compare the estimates of sensitivity and specificity
between models to check the robustness of our assumptions about
the variances of the random effects. If at least four studies that
evaluated different tests in the same study population were avail-
able (e.g. in studies that performed more than one index test in all
participants, individual index tests and combination of index tests
in all participants, or randomised controlled trials in which partic-
ipants were randomised to the different index tests), we planned
to perform a direct head-to-head comparison by limiting the test
comparison to such studies. We also planned to present the rel-
ative sensitivities and relative specificities of the index tests from
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the direct comparisons in a table.
We planned to perform the meta-analysis using the NLMIXED
command in SAS version 9.3 (SAS Institute Inc, Cary, North Car-
olina, USA). We planned to create a graph of pre-test probabili-
ties (using the observed median and range of prevalence from the
included studies) against post-test probabilities for each test strat-
ified by different thresholds and reference standards. The post-
test probabilities would have been calculated using these pre-test
probabilities and the summary positive and negative likelihood ra-
tios. The summary likelihood ratios and their confidence intervals
would have been calculated from the functions of the parameter
estimates from the bivariate model that we planned to fit to esti-
mate the summary sensitivities and specificities. Post-test proba-
bility associated with positive test is the probability of having the
target condition (acute pancreatitis or acute necrotising pancre-
atitis) on the basis of a positive test result, and is the same as the
term ’positive predictive value’ used in a single diagnostic accuracy
study. Post-test probability associated with a negative test is the
probability of having the target condition (acute pancreatitis or
acute necrotising pancreatitis) on the basis of a negative test result
and is 1 - ’negative predictive value’. Negative predictive value is
the term used in a single diagnostic accuracy study to indicate the
chance that the participant has no target condition when the test
is negative. We planned to report the summary sensitivity, speci-
ficity, positive and negative likelihood ratios, and post-test prob-
abilities for the median, lower quartile, and upper quartile of the
pre-test probabilities.
However, because of paucity of data, we did not perform anymeta-
analysis. We calculated the sensitivity and specificity of each test
and have reported these with their 95% confidence intervals (95%
CI), along with the post-test probability of positive and negative
test at the pre-test probability in the studies.
Investigations of heterogeneity
Of the nine sources of heterogeneity mentioned in the Secondary
objectives, we planned to use risk of bias, prospective or retrospec-
tive studies, publication status, presence or absence of infection,
and different test manufacturers as categorical covariates, and the
proportion of participants with a previous history of acute pan-
creatitis, the proportion of participants with different aetiologies,
the proportion of participants with pancreatic necrosis and peri-
pancreatic necrosis, and the average time to performance of the
test as continuous covariates in the regression model. As before,
we planned to include one covariate at a time in the regression
model and use the likelihood ratio test to determine whether the
covariate is statistically significant. We did not investigate hetero-
geneity because of the paucity of data.
Sensitivity analyses
We did not plan any sensitivity analyses except when the data
available from the studies were ambiguous (e.g. the numbers in the
text differed from the numbers in the figures), in which case we
planned to assess the impact of different data used by a sensitivity
analysis. We did not find any ambiguous data in the studies.
Assessment of reporting bias
We planned to investigate whether the summary sensitivity and
specificity were different between studies published as full text and
those that were available only as abstracts (at least two years prior to
the search date) using the methods described in the Investigations
of heterogeneity section. We did not investigate reporting bias
because of the paucity of data.
R E S U L T S
Results of the search
We identified a total of 23,360 references through the electronic
searches of MEDLINE (n = 7326), Embase (n = 11,502), Sci-
ence Citation Index Expanded (n = 4293), National Institute for
Health Research (NIHR HTA and DARE) (n = 142), Zetoc (n
= 360), WHO ICTRP (n = 1), and ClinicalTrials.gov (n = 36).
We excluded 10,657 duplicates and 12,790 clearly irrelevant ref-
erences through reading the titles or abstracts, or both. We sought
full-text articles for 213 references, but were unable to obtain the
full text for four references (Djurasinovic 2013; Grenier 1968;
Issekutz 2003; Pindak 2003). We retrieved the full-text articles of
209 references for further assessment against our review protocol
inclusion criteria. We excluded 204 of these 209 references for the
reasons provided in the Characteristics of excluded studies sec-
tion. Three studies (five references) fulfilled the inclusion criteria
and provided the diagnostic accuracy data for the review (Alfonso
2003; Bertsch 1997; Rau 1998). We have shown the reference
flow in Figure 2.
11Serum C-reactive protein, procalcitonin, and lactate dehydrogenase for the diagnosis of pancreatic necrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Study flow diagram.
12Serum C-reactive protein, procalcitonin, and lactate dehydrogenase for the diagnosis of pancreatic necrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Included studies
Three studies including 242 participants met the inclusion criteria
for this review and assessed the diagnostic accuracy of the index
tests in participants with established acute pancreatitis. The av-
erage age of participants in the studies was 49 years (Rau 1998),
53 years (Bertsch 1997), and 67 years (Alfonso 2003). About
two-fifths of participants (41%) were females in these three stud-
ies (Alfonso 2003; Bertsch 1997; Rau 1998). One study was
a prospective study (Rau 1998), and one was a retrospective
study (Alfonso 2003). It was unclear whether the third study was
prospective or retrospective (Bertsch 1997). All of the studies were
full-text publications. The studies did not report whether they in-
cluded participants with a previous history of acute pancreatitis.
Two studies reported that they included acute pancreatitis of var-
ied aetiology (Alfonso 2003; Bertsch 1997); information on aeti-
ology was not available in the third study (Rau 1998). None of the
studies reported data separately for different aetiologies. None of
the studies reported the presence or absence of infection in partic-
ipants. One study clearly indicated that the presence of pancreatic
and peripancreatic necrosis was considered as the target condition
(Rau 1998); the remaining studies did not provide this informa-
tion. None of the studies reported data separately for pancreatic
and peripancreatic necrosis.
One study reported the diagnostic performance of CRP for two
threshold levels (> 200 mg/L and > 279 mg/L) without stating
the day on which the CRP was measured (Alfonso 2003). One
study reported the diagnostic performance of procalcitonin on day
1 using a threshold level of 0.5 ng/mL (Bertsch 1997). One study
reported the diagnostic performance of CRP on day 3 using a
threshold level of 140 mg/L and LDH on day 5 using a threshold
level of 290 U/L (Rau 1998).
Excluded studies
We excluded a total of 204 studies at the full-text stage for the
following reasons.
• Not a primary study (editorial): 9 (Chen 2004; Fan 1994;
Folch-Puy 2007; Gosling 1992; Lipsett 2001; Lott 1991;
Manabe 2004; Petrov 2011; Samso 2002).
• Not a primary study (letter to editor): 6 (Beger 1989; Bihari
2004; Choudhary 2012; Economou 1997; Neoptolemos 2001;
Wilson 1989b).
• Not a primary study (review): 14 (Bassi 1994; Brailski
1975; Buchler 1991; Frossard 2001; Geng 2014; Johnson 2003;
Korczowski 2006; Lempinen 2005; Liu 2008; Malfertheiner
1993; Millat 1999; Mulholland 1996; Purkayastha 2006; Rau
2004).
• Case reports: 1 (Wong 1993).
• Inappropriate index test: 1 (Pezzilli 1998b).
• Inappropriate population: 1 (Machiedo 1974).
• Inadequate reference standard: 7 (Barauskas 2004; Cardoso
2013; Gluskina 1967; Khanna 2013; Pallisera 2014;
Puolakkainen 1987; Schaffler 2010).
• No diagnostic accuracy data on pancreatic necrosis: 165
(Abishek 2014; Aggelopoulos 1996; Ammori 2003; Appasani
2011a; Appasani 2011b; Appasani 2012; Bajec 2010; Bapat
1986; Berry 1982; Bezmarevic 2012a; Bezmarevic 2012b;
Bezmarevic 2012c; Blum 2001; Boskovic 2014; Brand 2014;
Brisinda 1999; Buchler 1986a; Buchler 1986b; Buchler 1986c;
Buchler 1987; Bulbuller 2006; Cai 2014; Cardoso 2011;
Cardoso 2015; Chen 1992; Chen 2012; Choi 2012; Choi 2013;
Chooklin 2010; Cooper 1981; Cravo 1988; d’Eril 2000;
Dambrauskas 2010; Dammann 1979; Daniel 2010; de Beaux
1996; De la Pena 1991; Del Prete 2001; Digalakis 2009;
Duarte-Rojo 2009; Ferguson 1990; Fisic 2013; Frasquet 2003;
Gao 2014; Garcia-Cantu 2004; Garcia Lozano 1992; Gelfand
2005; Gross 1990; Guenther 2010; Gurda-Duda 2008; Gurleyik
2004; Gurleyik 2005; Gvozdenovic 2001; Hamalainen 2002;
Han 2011; Hjalmarsson 2009; Huang 2013; Huang 2015;
Imamura 2002a; Imamura 2002b; Inagaki 1997; Isenmann
1993; Isogai 1998; Jia 2015; Jiang 2004; Jimenez 2015; Jimin
2015; Kaiyasah 2013; Kaya 2007; Kazda 2002; Khvatova 1973;
Khvatova 1977; Kibar 2016; Kim 2013a; Kim 2013b; Kitsanou
2004; Kusnierz-Cabala 2004; Kylanpaa-Back 2001a;
Kylanpaa-Back 2001b; Kylanpaa-Back 2001c; Leese 1987; Leese
1988; Lempinen 1999; Lewandowski 2007; Li 2013; Liang
2014; Lindner 1995; Lobo 1999; Ma 2013; Makay 2003;
Makela 2007; Mandi 2000a; Mandi 2000b; Manes 1994;
Mantke 2002; Marek 1996; Mayer 1984; Mayer 2002; Melzi
D’Eril 2000; Modrau 2005; Modzelewski 2005; Muller 1997;
Muller 2000; Nunes 2009; Oezcueruemez-Porsch 1998; Olah
2005; Omoto 2015; Ostrovskii 2012; Paajanen 1995; Palani
1977; Park 2012; Park 2013; Pezzilli 1994; Pezzilli 1995a;
Pezzilli 1995b; Pezzilli 1997; Pezzilli 1998a; Pezzilli 2000;
Pongprasobchai 2010; Qiu 2014; Raraty 2002; Rau 1997; Rau
2000; Rau 2007; Ricardo 2011; Riche 2003; Ruzafa 1991;
Sanchez-Lozada 2005; Santotoribio 2015; Sato 2004; Savel’ev
2002; Schaffler 2011; Sharma 2011; Stimac 2010; Stimac 2012;
Stimac 2013; Stoelben 1996; Sugumar 2011; Tao 2013;
Teerenhovi 1988; Tesinsky 2008; Trunin 1985; Uhl 1991;
Uomo 1995; Vaz 2013; Vesentini 1993; Viedma 1992; Viedma
1994; Vlachos 2014; Wei 2013; Wetherill 2012; Wetherill
2013a; Wetherill 2013b; Wilson 1987; Wilson 1988; Wilson
1989a; Woo 2011; Xu 2015; Yadav 2015a; Yadav 2015b; Yasuda
2011; Yin 2014; Yu 2011; Zhu 2013; Zrnic 2007).
Methodological quality of included studies
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Wehave summarised themethodological quality of included stud-
ies in Figure 3 and Figure 4.
Figure 3. Risk of bias and applicability concerns graph: review authors’ judgements about each domain
presented as percentages across included studies.
Figure 4. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study.
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Participant selection
All studies were at unclear risk of bias in the participant selection
domain and were also of unclear concern about applicability in
this domain, because none of the included studies mentioned if
participants were excluded inappropriately or whether a consecu-
tive or random selection of participants was included.
Index test
Two studies were at high risk of bias in the index test domain,
because the thresholds used were not prespecified; it was also un-
clear whether the index tests were interpreted without knowledge
of the reference standard (Alfonso 2003; Rau 1998). One study
had an unclear risk of bias, because it was unclear whether the
index tests were interpreted without knowledge of the reference
standard (Bertsch 1997). However, all studies were of low concern
with regards to applicability since all studies reported the thresh-
old at which the diagnosis was made.
Reference standard
All studies were at high risk of bias in the reference standard
domain; in two studies the reference standard was CECT alone
(Alfonso 2003; Bertsch 1997), and in the third study the reference
standard was a combination of CT scan and laparotomy findings
(Rau 1998). We considered all of the studies to be low concern
with regards to applicability since they all used pancreatic or peri-
pancreatic necrosis, or both as the target condition.
Flow and timing
All studies were at high risk of bias in this domain because the
interval between the measurement of the index test and the refer-
ence standard in all studies was longer than 24 hours.
Findings
Since the studies reported the tests at different thresholds, we did
not perform meta-analysis. The sensitivities and specificities and
their 95% confidence intervals (CI) are visually represented in the
forest plots and ROC space in Figure 5 and Figure 6. The sensi-
tivities and specificities are summarised in Summary of findings.
The median pre-test probability in the studies was 53.3%. The
days indicate the number of days after admission that the mea-
surements were made.
Figure 5. Forest plot of tests: 1 C-reactive protein (day 3) > 140 mg/L; 2 C-reactive protein (day not stated)
> 200 mg/L; 3 C-reactive protein (day not stated) > 279 mg/L; 4 Procalcitonin (day 1) > 0.5 ng/mL; 5 Lactate
dehydrogenase (day 5) > 290 U/L.
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Figure 6. Summary ROC plot of tests: 1 C-reactive protein (day 3) > 140 mg/L; 2 C-reactive protein (day
not stated) > 200 mg/L; 3 C-reactive protein (day not stated) > 279 mg/L; 4 Procalcitonin (day 1) > 0.5 ng/mL; 5
Lactate dehydrogenase (day 5) > 290 U/L.
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C-reactive protein
Day 3: > 140 mg/L
One study including 70 participants reported the diagnostic accu-
racy of day 3 CRP at threshold > 140 mg/L (Rau 1998). The sen-
sitivity and specificity of CRP at this threshold was 0.82 (95% CI
0.66 to 0.92) and 0.84 (95% CI 0.66 to 0.95), respectively. The
positive and negative likelihood ratios were 5.08 (95% CI 2.25 to
11.50) and 0.21 (95% CI 0.11 to 0.43), respectively. At the pre-
test probability of 53.3%, the post-test probabilities of pancreatic
necrosis of positive and negative tests were 85.3% (95%CI 72.0%
to 92.9%) and 19.7% (95% CI 10.9% to 32.7%), respectively.
Day not stated: > 200 mg/L
One study including 157 participants reported the diagnostic ac-
curacy of CRP (day not stated) at threshold > 200 mg/L (Alfonso
2003). The sensitivity and specificity of CRP at this threshold was
0.88 (95% CI 0.69 to 0.97) and 0.75 (95% CI 0.67 to 0.82),
respectively. The positive and negative likelihood ratios were 3.52
(95% CI 2.53 to 4.89) and 0.16 (95% CI 0.06 to 0.46), respec-
tively. At the pre-test probability of 53.3%, the post-test proba-
bilities of pancreatic necrosis of positive and negative tests were
80.1% (95% CI 74.3% to 84.8%) and 15.5% (95% CI 5.9% to
34.7%), respectively.
Day not stated: > 290 mg/L
One study including 157 participants reported the diagnostic ac-
curacy of CRP (day not stated) at threshold > 290 mg/L (Alfonso
2003). The sensitivity and specificity of CRP at this threshold was
0.72 (95% CI 0.51 to 0.88) and 0.89 (95% CI 0.82 to 0.93),
respectively. The positive and negative likelihood ratios were 6.34
(95% CI 3.71 to 10.82) and 0.32 (95% CI 0.17 to 0.59), respec-
tively. At the pre-test probability of 53.3%, the post-test proba-
bilities of pancreatic necrosis of positive and negative tests were
87.9% (95% CI 80.9% to 92.5%) and 26.5% (95% CI 16.1% to
40.4%), respectively.
Procalcitonin (day 1 > 0.5 ng/mL)
One study including 15 participants reported the diagnostic ac-
curacy of day 1 procalcitonin at threshold > 0.5 ng/mL (Bertsch
1997). The sensitivity and specificity of procalcitonin at this
threshold was 0.75 (95%CI 0.35 to 0.97) and 0.57 (95% CI 0.18
to 0.90), respectively. The positive and negative likelihood ratios
were 55.79 (95% CI 3.64 to 856.23) and 0.13 (95% CI 0.06 to
0.29), respectively. At the pre-test probability of 53.3%, the post-
test probabilities of pancreatic necrosis of positive and negative
tests were 66.7% (95% CI 43.8% to 83.7%) and 33.3% (95% CI
11.4% to 66.1%), respectively.
Lactate dehydrogenase (day 5 > 290 U/L)
One study including 70 participants reported the diagnostic ac-
curacy of day 5 LDH at threshold > 0.5 ng/mL (Rau 1998). The
sensitivity and specificity of LDH at this threshold was 0.87 (95%
CI 0.73 to 0.96) and 1.00 (95%CI 0.89 to 1.00), respectively. The
positive and negative likelihood ratios were 1.75 (95% CI 0.68 to
4.50) and 0.44 (95% CI 0.11 to 1.71), respectively. At the pre-
test probability of 53.3%, the post-test probabilities of pancreatic
necrosis of positive and negative tests were 98.5% (95%CI 80.6%
to 99.9%) and 12.8% (95% CI 6.1% to 24.9%), respectively.
Investigation of heterogeneity and reporting bias
We did not investigate heterogeneity because of the paucity of
data. We did not assess reporting bias since all of the studies were
full-text publications.
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Summary of findings
Population People with acute pancreat it is
Setting Secondary care in various countries
Target condi-
tion
Acute pancreat ic (or peripancreat ic) necrosis
Reference
standard
Radiology (contrast enhanced computed tomography scan) or surgery
M e-
dian preva-
lence of pan-
creatic leak
53.3%
Index test1 Sensitivity Specificity Study specific
pre- test prob-
ability
Post- test
probability of
a positive test
2
Post-
test probabil-
ity of a nega-
tive test2
Number of
studies
Number of
participants
Risk of bias Applicability
concerns
Plain language
interpretation
C-react ive
protein (day 3)
> 140 mg/ L
0.82 (95% CI
0.66 to 0.92)
0.84 (95% CI
0.66 to 0.95)
55.7% 85.3% (95% CI
72.0% to 92.
9%)
19.7% (95% CI
10.9% to 32.
7%)
1 70 High Unclear At the pre-
test probabil-
ity of 56%, out
of 100 people
with posit ive
test, 85 people
(95% CI 72 to
93) have pan-
creat ic necro-
sis. At the
same pre-test
probability, out
of 100 people
with negat ive
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test, 20 people
(95% CI 11 to
33) have pan-
creat ic necro-
sis
C-
react ive pro-
tein (day not
stated) > 200
mg/ L
0.88 (95% CI
0.69 to 0.97)
0.75 (95% CI
0.67 to 0.82)
15.9% 80.1% (95% CI
74.3% to 84.
8%)
15.5% (95% CI
5.9% to 34.
7%)
1 157 High Unclear At the pre-
test probabil-
ity of 16%, out
of 100 people
with posit ive
test, 80 people
(95% CI 74 to
85) have pan-
creat ic necro-
sis. At the
same pre-test
probability, out
of 100 people
with negat ive
test, 16 people
(95% CI 6 to
35) have pan-
creat ic necro-
sis
C-
react ive pro-
tein (day not
stated) > 279
mg/ L
0.72 (95% CI
0.51 to 0.88)
0.89 (95% CI
0.82 to 0.93)
15.9% 87.9% (95% CI
80.9% to 92.
5%)
26.5% (95% CI
16.1% to 40.
4%)
1 157 High Unclear At the pre-
test probabil-
ity of 16%, out
of 100 people
with posit ive
test, 88 people
(95% CI 81 to
93) have pan-
creat ic necro-
sis. At the
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same pre-test
probability, out
of 100 people
with negat ive
test, 27 people
(95% CI 16 to
40) have pan-
creat ic necro-
sis
Procalci-
tonin (day 1) >
0.5 ng/ mL
0.75 (95% CI
0.35 to 0.97)
0.57 (95% CI
0.18 to 0.90)
53.3% 66.7% (95% CI
43.8% to 83.
7%)
33.3% (95% CI
11.4% to 66.
1%)
1 15 High Unclear At the pre-
test probabil-
ity of 56%, out
of 100 people
with posit ive
test, 67 people
(95% CI 44 to
84) have pan-
creat ic necro-
sis. At the
same pre-test
probability, out
of 100 people
with negat ive
test, 33 people
(95% CI 11 to
66) have pan-
creat ic necro-
sis
Lactate dehy-
drogenase
(day 5) > 290
U/ L
0.87 (95% CI
0.73 to 0.96)
1.00 (95% CI
0.89 to 1.00)
55.7% 98.5% (95% CI
80.6% to 99.
9%)
12.8% (95% CI
6.1% to 24.
9%)
1 70 High Unclear At the median
pre-test proba-
bility of 56%,
out of 100 peo-
ple with posi-
t ive
test, 99 people
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(95% CI 81 to
100) have pan-
creat ic necro-
sis. At the
same pre-test
probability, out
of 100 people
with negat ive
test, 13 people
(95% CI 6 to
25) have pan-
creat ic necro-
sis
Intepretation: Lactate dehydrogenase (day 5) > 290 U/ L appears to perform best, m issing the diagnosis in 13 (95% CI 4 to 27) out of 100 people with acute pancreat ic necrosis
and overdiagnosing in 0 (95% CI 0 to 11) out of 100 people without acute pancreat ic necrosis. However, the study is at high risk of bias, and neither the day on which the
measurement was made nor the threshold for posit ive diagnosis was determined in advance, which is likely to increase the test performance incorrect ly. Consequent ly, the
results are highly unreliable
1The number following ’day’ indicates the number of days af ter admission that the index test was performed. The information
that follows this indicates the threshold.
2 The post-test probabilit ies were calculated at the median pre-test probability.
CI: conf idence interval
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D I S C U S S I O N
Summary of main results
Three studies including 242 participants met the inclusion criteria
for this review and assessed the diagnostic accuracy of the index
tests in participants with established acute pancreatitis (Alfonso
2003; Bertsch 1997; Rau 1998). These three studies reported the
diagnostic test accuracy of the index tests at different thresholds
and different time points. C-reactive protein was assessed at three
different time points (day 3 and not known for two thresholds),
and the point estimate of the sensitivities ranged from0.72 to 0.88,
while the point estimate of the specificities ranged from 0.75 to
0.89. The confidence intervals of the sensitivities ranged from0.51
to 0.97, and those of the specificities ranged from 0.66 to 0.93.
Procalcitonin was assessed on day 1 using a threshold of 0.5 ng/
mL, and LDH was assessed on day 5 using a threshold of 290 U/
L. The sensitivity and specificity of procalcitonin were 0.75 (95%
CI 0.35 to 0.97) and 0.57 (95% CI 0.18 to 0.90), respectively,
while the sensitivity and specificity of LDH were 0.87 (95% CI
0.73 to 0.96) and 1.00 (95% CI 0.89 to 1.00), respectively.
Avoiding CECT may be beneficial to the patient, as it avoids un-
necessary radiation exposure, particularly if the patient has under-
gone CECT for the diagnosis of acute pancreatitis. It also bene-
fits the healthcare funder, as it can decrease costs thereby allow-
ing limited resources to be used more appropriately. In addition,
patients with acute gallstone pancreatitis may be able to undergo
early laparoscopic cholecystectomy, if the patient is stable and
acute necrotising pancreatitis can be ruled out early. A triage test
to avoid CECT is thus useful. However, such a triage test should
have high sensitivity with at least a reasonable specificity. If it has
a low specificity, it is not a useful triage test even if it has a very
high sensitivity, since one might skip the test altogether and per-
form CECT directly. The sensitivity of the tests varied and was
moderate, with mean sensitivities between 0.75 and 0.89 for all
of the tests. This means that these tests can miss about 11% to
25% of people with pancreatic necrosis. To miss 11% to 25% of
people with pancreatic necrosis is unacceptable clinically, as pa-
tients can be discharged or denied further investigations or inten-
sive treatment. Overall, none of the tests assessed in this review was
sufficiently accurate to suggest that they may be useful in clinical
practice. In clinical practice, a rising trend is usually considered
important rather than a single value, although very high values of
CRP or LDH along with organ failure will raise the suspicion of
necrotising pancreatitis. However, we were unable to determine
the accuracy of a rising trend in CRP or LDH, as none of the
studies reported this information.
Strengths and weaknesses of the review
Strengths
One of themain strengths of this review was that the literature was
searched thoroughly, without any publication or language restric-
tions. We did not use any diagnostic test accuracy filters in our
literature search because such filters could have led to the exclusion
of some relevant studies (Doust 2005). Inclusion of abstracts and
non-English articles may decrease the impact of publication bias
to a certain extent, although the determinants and extent of publi-
cation bias and selective reporting are not well known for diagnos-
tic accuracy studies. We also planned to exclude case-control stud-
ies because these studies are prone to bias (Whiting 2011). Two
review authors (OK and KSG) independently searched the refer-
ences located by the search to identify relevant studies, screened
the full-text papers against the inclusion criteria, and extracted
data. Data extractions by two review authors potentially reduced
the chance of errors related to data extraction by a single review au-
thor (Buscemi 2006). Another strength of this review was that we
used the recommended methodological quality methods to assess
the risk of bias and applicability concerns in the included studies
and took these into consideration while interpreting the evidence.
Weaknesses
There were several shortcomings in our review. Firstly, the stud-
ies included in the review had several methodological deficiencies.
The major methodological deficiency was that the two studies
that contributed the most participants to this review did not use a
prespecified threshold (Alfonso 2003; Rau 1998). In one of these
studies it was unclear how the day on which the measurement
was performed was determined (Alfonso 2003), while in the other
study, the day of measurement was determined by selecting the
day (along with the threshold) on which the test had maximum
accuracy (Rau 1998). This is likely to overestimate the diagnostic
accuracy. In addition, none of the studies reported whether the in-
dex tests and reference standards were interpreted independently
of each other. If they were not interpreted independently of each
other, the accuracy of the tests would have been overestimated.
None of the studies reported whether all the participants were
included in the study. Exclusion of participants with borderline
values close to the threshold used or participants with other causes
of elevation of these tests will overestimate the diagnostic test ac-
curacy of these tests.
Secondly, the sample sizes in the studies were small, resulting in
wide confidence intervals. It was not possible to perform a meta-
analysis to improve the precision since the studies reported the
tests on different days of admission using different thresholds.
Additionally, the measurement of CRP on different days using
different thresholds for diagnosis of pancreatic necrosis made it
impossible for us to explore whether the results could be replicated
in another group of participants.
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Comparison with other reviews
We did not identify any other systematic reviews on the topic.
Applicability of findings to the review question
Generalisability of the results
The studies did not restrict the participants to specific aetiologies
of acute pancreatitis, therefore the findings of this review are appli-
cable to all aetiologies of acute pancreatitis. Although the studies
did not specify the restriction of participants to acute severe pan-
creatitis, it is likely that two studies used these tests in participants
with acute severe pancreatitis, since more than 50% of partici-
pants in these studies had pancreatic necrosis (Bertsch 1997; Rau
1998). These two studies reported procalcitonin and LDH along
with CRP > 140 mg/L (Bertsch 1997; Rau 1998). Consequently,
the results of these two studies are applicable to people with severe
pancreatitis, while the results from the third study, which reported
CRP > 200 mg/L and CRP > 290 mg/L (Alfonso 2003), are ap-
plicable to all people with acute pancreatitis.
Use of the test in clinical setting
The main role of the index test is as a triage test to identify people
who require further scanning such as CT. Such a test needs to be
highly sensitive with at least reasonable specificity, so that it is pos-
sible to rule out pancreatic necrosis, which will avoid further test-
ing. The confidence intervals of post-test probability of a negative
test ranged from 1% to 66.1% when the pre-test probability was
15.9%, and from 5.9% to 66.1% when the pre-test probability
was 53.3%. Adding to the uncertainty due to random errors re-
sulting from small sample sizes, there were many systematic errors,
resulting in further uncertainty. Given these uncertainties, the role
of these tests in people with acute pancreatitis is not clear.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Because of the paucity of data and methodological deficiencies in
the studies, it was not possible to arrive at any conclusions regard-
ing the diagnostic test accuracy of C-reactive protein, procalci-
tonin, and lactate dehydrogenase.
Implications for research
Further well-designed diagnostic test accuracy studies with a pre-
specified index test threshold of C-reactive protein, procalcitonin,
and lactate dehydrogenase, as well as appropriate follow-up (for
at least two weeks to ensure that the person does not have pan-
creatic necrosis; early scans may not indicate pancreatic necrosis)
and a clearly defined reference standard (of surgical or radiological
confirmation of pancreatic necrosis) are important to determine
the diagnostic accuracy of C-reactive protein, procalcitonin, and
lactate dehydrogenase reliably.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alfonso 2003
Study characteristics Study characteristics
Patient sampling Type of study: retrospective study.
Consecutive or random sample: unclear.
Patient characteristics and set-
ting
Sample size: 157.
Females: 63 (40.1%).
Age: 67 years.
Presentation:
Participants with acute pancreatitis.
Setting: secondary setting in Spain.
Index tests Index test: C-reactive protein (day not stated).
Further details:
Technical specifications: Nephelometry (Dade Behring Marburg GmbH, Marburg, Germany).
Performed by: not stated.
Criteria for positive diagnosis: > 200 mg/L and > 279 mg/L.
Target condition and reference
standard(s)
Target condition: pancreatic necrosis.
Reference standard: CT scan.
Flow and timing Number of indeterminates for whom the results of reference standard were available: 0 (0%).
Number of participants who were excluded from the analysis: not stated
Comparative
Notes This study reported the diagnostic test accuracy at 2 threshold levels
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear Unclear
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Alfonso 2003 (Continued)
DOMAIN 2: Index Test All tests DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
High Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
No
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
High
Bertsch 1997
Study characteristics Study characteristics
Patient sampling Type of study: unclear whether prospective or retrospective study.
Consecutive or random sample: unclear.
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Bertsch 1997 (Continued)
Patient characteristics and set-
ting
Sample size: 15.
Females: 5 (33.3%).
Age: 53 years.
Presentation:
Participants with acute pancreatitis.
Setting: secondary care setting, Germany.
Index tests Index test: procalcitonin (day 1).
Further details:
Technical specifications: a luminometric immunoassay (Fa.Brahms, Berlin).
Performed by: not stated.
Criteria for positive diagnosis: > 0.5 ng/mL.
Target condition and reference
standard(s)
Target condition: pancreatic necrosis.
Reference standard: CT scan.
Further details:
Technical specifications: not stated.
Performed by: not stated.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: 0 (0%).
Number of participants who were excluded from the analysis: not stated
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear Unclear
DOMAIN 2: Index Test All tests DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
Unclear
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Bertsch 1997 (Continued)
dard?
If a threshold was used, was it
pre-specified?
Yes
Unclear Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
High Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
No
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Unclear
High
Rau 1998
Study characteristics Study characteristics
Patient sampling Type of study: prospective study.
Consecutive or random sample: unclear.
Patient characteristics and set-
ting
Sample size: 70.
Females: 31 (44.3%).
Age: 49 years.
Presentation:
Participants with acute pancreatitis (within fewer than 4 days of onset of symptoms).
Setting: secondary care setting, Germany.
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Rau 1998 (Continued)
Index tests Index test: C-reactive protein (day 3).
Further details:
Technical specifications: laser nephelometry.
Performed by: not stated.
Criteria for positive diagnosis: > 140 mg/L.
Index test: lactate dehydrogenase (day 5).
Further details:
Technical specifications: enzyme kinetic method.
Performed by: not stated.
Criteria for positive diagnosis: > 290 U/L.
Target condition and reference
standard(s)
Target condition: pancreatic necrosis.
Reference standard: CT scan or intra-operative findings, or both.
Further details:
Technical specifications: CT scan: CT9800 (General Electric) andCTTwin Flash (Elscint); Surgery:
not applicable.
Performed by: not stated.
Criteria for positive diagnosis: not stated.
Flow and timing Number of indeterminates for whom the results of reference standard were available: 0 (0%).
Number of participants who were excluded from the analysis: not stated
Comparative
Notes This study reported 2 index tests.
Authors provided additional information that the index tests were interpreted without knowledge
of reference standards. The authors also stated that the interval between the index tests and CT scan
was 2 to 6 days, and the interval between index tests and laparotomy was 18 days
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear Unclear
DOMAIN 2: Index Test All tests DOMAIN 2: Index
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Rau 1998 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
High Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Unclear
High
CT: computed tomography
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abishek 2014 No diagnostic accuracy data on pancreatic necrosis
Aggelopoulos 1996 No diagnostic accuracy data on pancreatic necrosis
Ammori 2003 No diagnostic accuracy data on pancreatic necrosis
Appasani 2011a No diagnostic accuracy data on pancreatic necrosis
Appasani 2011b No diagnostic accuracy data on pancreatic necrosis
Appasani 2012 No diagnostic accuracy data on pancreatic necrosis
Bajec 2010 No diagnostic accuracy data on pancreatic necrosis
Bapat 1986 No diagnostic accuracy data on pancreatic necrosis
Barauskas 2004 Inadequate reference standard
Bassi 1994 Not a primary study (review)
Beger 1989 Not a primary study (letter to editor)
Berry 1982 No diagnostic accuracy data on pancreatic necrosis
Bezmarevic 2012a No diagnostic accuracy data on pancreatic necrosis
Bezmarevic 2012b No diagnostic accuracy data on pancreatic necrosis
Bezmarevic 2012c No diagnostic accuracy data on pancreatic necrosis
Bihari 2004 Not a primary study (letter to editor)
Blum 2001 No diagnostic accuracy data on pancreatic necrosis
Boskovic 2014 No diagnostic accuracy data on pancreatic necrosis
Brailski 1975 Not a primary study (review)
Brand 2014 No diagnostic accuracy data on pancreatic necrosis
Brisinda 1999 No diagnostic accuracy data on pancreatic necrosis
Buchler 1986a No diagnostic accuracy data on pancreatic necrosis
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(Continued)
Buchler 1986b No diagnostic accuracy data on pancreatic necrosis
Buchler 1986c No diagnostic accuracy data on pancreatic necrosis
Buchler 1987 No diagnostic accuracy data on pancreatic necrosis
Buchler 1991 Not a primary study (review)
Bulbuller 2006 No diagnostic accuracy data on pancreatic necrosis
Cai 2014 No diagnostic accuracy data on pancreatic necrosis
Cardoso 2011 No diagnostic accuracy data on pancreatic necrosis
Cardoso 2013 Inadequate reference standard
Cardoso 2015 No diagnostic accuracy data on pancreatic necrosis
Chen 1992 No diagnostic accuracy data on pancreatic necrosis
Chen 2004 Not a primary study (editorial)
Chen 2012 No diagnostic accuracy data on pancreatic necrosis
Choi 2012 No diagnostic accuracy data on pancreatic necrosis
Choi 2013 No diagnostic accuracy data on pancreatic necrosis
Chooklin 2010 No diagnostic accuracy data on pancreatic necrosis
Choudhary 2012 Not a primary study (letter to editor)
Cooper 1981 No diagnostic accuracy data on pancreatic necrosis
Cravo 1988 No diagnostic accuracy data on pancreatic necrosis
d’Eril 2000 No diagnostic accuracy data on pancreatic necrosis
Dambrauskas 2010 No diagnostic accuracy data on pancreatic necrosis
Dammann 1979 No diagnostic accuracy data on pancreatic necrosis
Daniel 2010 No diagnostic accuracy data on pancreatic necrosis
de Beaux 1996 No diagnostic accuracy data on pancreatic necrosis
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(Continued)
De la Pena 1991 No diagnostic accuracy data on pancreatic necrosis
Del Prete 2001 No diagnostic accuracy data on pancreatic necrosis
Digalakis 2009 No diagnostic accuracy data on pancreatic necrosis
Duarte-Rojo 2009 No diagnostic accuracy data on pancreatic necrosis
Economou 1997 Not a primary study (letter to editor)
Fan 1994 Not a primary study (editorial)
Ferguson 1990 No diagnostic accuracy data on pancreatic necrosis
Fisic 2013 No diagnostic accuracy data on pancreatic necrosis
Folch-Puy 2007 Not a primary study (editorial)
Frasquet 2003 No diagnostic accuracy data on pancreatic necrosis
Frossard 2001 Not a primary study (review)
Gao 2014 No diagnostic accuracy data on pancreatic necrosis
Garcia Lozano 1992 No diagnostic accuracy data on pancreatic necrosis
Garcia-Cantu 2004 No diagnostic accuracy data on pancreatic necrosis
Gelfand 2005 No diagnostic accuracy data on pancreatic necrosis
Geng 2014 Not a primary study (review)
Gluskina 1967 Inadequate reference standard
Gosling 1992 Not a primary study (editorial)
Gross 1990 No diagnostic accuracy data on pancreatic necrosis
Guenther 2010 No diagnostic accuracy data on pancreatic necrosis
Gurda-Duda 2008 No diagnostic accuracy data on pancreatic necrosis
Gurleyik 2004 No diagnostic accuracy data on pancreatic necrosis
Gurleyik 2005 No diagnostic accuracy data on pancreatic necrosis
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(Continued)
Gvozdenovic 2001 No diagnostic accuracy data on pancreatic necrosis
Hamalainen 2002 No diagnostic accuracy data on pancreatic necrosis
Han 2011 No diagnostic accuracy data on pancreatic necrosis
Hjalmarsson 2009 No diagnostic accuracy data on pancreatic necrosis
Huang 2013 No diagnostic accuracy data on pancreatic necrosis
Huang 2015 No diagnostic accuracy data on pancreatic necrosis
Imamura 2002a No diagnostic accuracy data on pancreatic necrosis
Imamura 2002b No diagnostic accuracy data on pancreatic necrosis
Inagaki 1997 No diagnostic accuracy data on pancreatic necrosis
Isenmann 1993 No diagnostic accuracy data on pancreatic necrosis
Isogai 1998 No diagnostic accuracy data on pancreatic necrosis
Jia 2015 No diagnostic accuracy data on pancreatic necrosis
Jiang 2004 No diagnostic accuracy data on pancreatic necrosis
Jimenez 2015 No diagnostic accuracy data on pancreatic necrosis
Jimin 2015 No diagnostic accuracy data on pancreatic necrosis
Johnson 2003 Not a primary study (review)
Kaiyasah 2013 No diagnostic accuracy data on pancreatic necrosis
Kaya 2007 No diagnostic accuracy data on pancreatic necrosis
Kazda 2002 No diagnostic accuracy data on pancreatic necrosis
Khanna 2013 Inadequate reference standard
Khvatova 1973 No diagnostic accuracy data on pancreatic necrosis
Khvatova 1977 No diagnostic accuracy data on pancreatic necrosis
Kibar 2016 No diagnostic accuracy data on pancreatic necrosis
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(Continued)
Kim 2013a No diagnostic accuracy data on pancreatic necrosis
Kim 2013b No diagnostic accuracy data on pancreatic necrosis
Kitsanou 2004 No diagnostic accuracy data on pancreatic necrosis
Korczowski 2006 Not a primary study (review)
Kusnierz-Cabala 2004 No diagnostic accuracy data on pancreatic necrosis
Kylanpaa-Back 2001a No diagnostic accuracy data on pancreatic necrosis
Kylanpaa-Back 2001b No diagnostic accuracy data on pancreatic necrosis
Kylanpaa-Back 2001c No diagnostic accuracy data on pancreatic necrosis
Leese 1987 No diagnostic accuracy data on pancreatic necrosis
Leese 1988 No diagnostic accuracy data on pancreatic necrosis
Lempinen 1999 No diagnostic accuracy data on pancreatic necrosis
Lempinen 2005 Not a primary study (review)
Lewandowski 2007 No diagnostic accuracy data on pancreatic necrosis
Li 2013 No diagnostic accuracy data on pancreatic necrosis
Liang 2014 No diagnostic accuracy data on pancreatic necrosis
Lindner 1995 No diagnostic accuracy data on pancreatic necrosis
Lipsett 2001 Not a primary study (editorial)
Liu 2008 Not a primary study (review)
Lobo 1999 No diagnostic accuracy data on pancreatic necrosis
Lott 1991 Not a primary study (editorial)
Ma 2013 No diagnostic accuracy data on pancreatic necrosis
Machiedo 1974 Inappropriate population
Makay 2003 No diagnostic accuracy data on pancreatic necrosis
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(Continued)
Makela 2007 No diagnostic accuracy data on pancreatic necrosis
Malfertheiner 1993 Not a primary study (review)
Manabe 2004 Not a primary study (editorial)
Mandi 2000a No diagnostic accuracy data on pancreatic necrosis
Mandi 2000b No diagnostic accuracy data on pancreatic necrosis
Manes 1994 No diagnostic accuracy data on pancreatic necrosis
Mantke 2002 No diagnostic accuracy data on pancreatic necrosis
Marek 1996 No diagnostic accuracy data on pancreatic necrosis
Mayer 1984 No diagnostic accuracy data on pancreatic necrosis
Mayer 2002 No diagnostic accuracy data on pancreatic necrosis
Melzi D’Eril 2000 No diagnostic accuracy data on pancreatic necrosis
Millat 1999 Not a primary study (review)
Modrau 2005 No diagnostic accuracy data on pancreatic necrosis
Modzelewski 2005 No diagnostic accuracy data on pancreatic necrosis
Mulholland 1996 Not a primary study (review)
Muller 1997 No diagnostic accuracy data on pancreatic necrosis
Muller 2000 No diagnostic accuracy data on pancreatic necrosis
Neoptolemos 2001 Not a primary study (letter to editor)
Nunes 2009 No diagnostic accuracy data on pancreatic necrosis
Oezcueruemez-Porsch 1998 No diagnostic accuracy data on pancreatic necrosis
Olah 2005 No diagnostic accuracy data on pancreatic necrosis
Omoto 2015 No diagnostic accuracy data on pancreatic necrosis
Ostrovskii 2012 No diagnostic accuracy data on pancreatic necrosis
47Serum C-reactive protein, procalcitonin, and lactate dehydrogenase for the diagnosis of pancreatic necrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Paajanen 1995 No diagnostic accuracy data on pancreatic necrosis
Palani 1977 No diagnostic accuracy data on pancreatic necrosis
Pallisera 2014 Inadequate reference standard
Park 2012 No diagnostic accuracy data on pancreatic necrosis
Park 2013 No diagnostic accuracy data on pancreatic necrosis
Petrov 2011 Not a primary study (editorial)
Pezzilli 1994 No diagnostic accuracy data on pancreatic necrosis
Pezzilli 1995a No diagnostic accuracy data on pancreatic necrosis
Pezzilli 1995b No diagnostic accuracy data on pancreatic necrosis
Pezzilli 1997 No diagnostic accuracy data on pancreatic necrosis
Pezzilli 1998a No diagnostic accuracy data on pancreatic necrosis
Pezzilli 1998b Inappropriate index test
Pezzilli 2000 No diagnostic accuracy data on pancreatic necrosis
Pongprasobchai 2010 No diagnostic accuracy data on pancreatic necrosis
Puolakkainen 1987 Inappropriate reference standards
Purkayastha 2006 Not a primary study (review)
Qiu 2014 No diagnostic accuracy data on pancreatic necrosis
Raraty 2002 No diagnostic accuracy data on pancreatic necrosis
Rau 1997 No diagnostic accuracy data on pancreatic necrosis
Rau 2000 No diagnostic accuracy data on pancreatic necrosis
Rau 2004 Not a primary study (review)
Rau 2007 No diagnostic accuracy data on pancreatic necrosis
Ricardo 2011 No diagnostic accuracy data on pancreatic necrosis
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(Continued)
Riche 2003 No diagnostic accuracy data on pancreatic necrosis
Ruzafa 1991 No diagnostic accuracy data on pancreatic necrosis
Samso 2002 Not a primary study (editorial)
Sanchez-Lozada 2005 No diagnostic accuracy data on pancreatic necrosis
Santotoribio 2015 No diagnostic accuracy data on pancreatic necrosis
Sato 2004 No diagnostic accuracy data on pancreatic necrosis
Savel’ev 2002 No diagnostic accuracy data on pancreatic necrosis
Schaffler 2010 inadequate reference standard
Schaffler 2011 No diagnostic accuracy data on pancreatic necrosis
Sharma 2011 No diagnostic accuracy data on pancreatic necrosis
Stimac 2010 No diagnostic accuracy data on pancreatic necrosis
Stimac 2012 No diagnostic accuracy data on pancreatic necrosis
Stimac 2013 No diagnostic accuracy data on pancreatic necrosis
Stoelben 1996 No diagnostic accuracy data on pancreatic necrosis
Sugumar 2011 No diagnostic accuracy data on pancreatic necrosis
Tao 2013 No diagnostic accuracy data on pancreatic necrosis
Teerenhovi 1988 No diagnostic accuracy data on pancreatic necrosis
Tesinsky 2008 No diagnostic accuracy data on pancreatic necrosis
Trunin 1985 No diagnostic accuracy data on pancreatic necrosis
Uhl 1991 No diagnostic accuracy data on pancreatic necrosis
Uomo 1995 No diagnostic accuracy data on pancreatic necrosis
Vaz 2013 No diagnostic accuracy data on pancreatic necrosis
Vesentini 1993 No diagnostic accuracy data on pancreatic necrosis
49Serum C-reactive protein, procalcitonin, and lactate dehydrogenase for the diagnosis of pancreatic necrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Viedma 1992 No diagnostic accuracy data on pancreatic necrosis
Viedma 1994 No diagnostic accuracy data on pancreatic necrosis
Vlachos 2014 No diagnostic accuracy data on pancreatic necrosis
Wei 2013 No diagnostic accuracy data on pancreatic necrosis
Wetherill 2012 No diagnostic accuracy data on pancreatic necrosis
Wetherill 2013a No diagnostic accuracy data on pancreatic necrosis
Wetherill 2013b No diagnostic accuracy data on pancreatic necrosis
Wilson 1987 No diagnostic accuracy data on pancreatic necrosis
Wilson 1988 No diagnostic accuracy data on pancreatic necrosis
Wilson 1989a No diagnostic accuracy data on pancreatic necrosis
Wilson 1989b Not a primary study (letter to editor)
Wong 1993 Case reports
Woo 2011 No diagnostic accuracy data on pancreatic necrosis
Xu 2015 No diagnostic accuracy data on pancreatic necrosis
Yadav 2015a No diagnostic accuracy data on pancreatic necrosis
Yadav 2015b No diagnostic accuracy data on pancreatic necrosis
Yasuda 2011 No diagnostic accuracy data on pancreatic necrosis
Yin 2014 No diagnostic accuracy data on pancreatic necrosis
Yu 2011 No diagnostic accuracy data on pancreatic necrosis
Zhu 2013 No diagnostic accuracy data on pancreatic necrosis
Zrnic 2007 No diagnostic accuracy data on pancreatic necrosis
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Characteristics of studies awaiting classification [ordered by study ID]
Djurasinovic 2013
Study characteristics Study characteristics
Patient sampling Unable to obtain full text
Patient characteristics and set-
ting
Index tests
Target condition and reference
standard(s)
Flow and timing
Comparative
Notes
Grenier 1968
Study characteristics Study characteristics
Patient sampling Unable to obtain full text
Patient characteristics and set-
ting
Index tests
Target condition and reference
standard(s)
Flow and timing
Comparative
Notes
Issekutz 2003
Study characteristics Study characteristics
Patient sampling Unable to obtain full text
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Issekutz 2003 (Continued)
Patient characteristics and set-
ting
Index tests
Target condition and reference
standard(s)
Flow and timing
Comparative
Notes
Pindak 2003
Study characteristics Study characteristics
Patient sampling Unable to obtain full text
Patient characteristics and set-
ting
Index tests
Target condition and reference
standard(s)
Flow and timing
Comparative
Notes
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D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 C-reactive protein (day 3) > 140
mg/L
1 70
2 C-reactive protein (day not
stated) > 200 mg/L
1 157
3 C-reactive protein (day not
stated) > 279 mg/L
1 157
4 Procalcitonin (day 1) > 0.5
ng/mL
1 15
5 Lactate dehydrogenase (day 5) >
290 U/L
1 70
Test 1. C-reactive protein (day 3) > 140 mg/L.
Review: Serum C-reactive protein, procalcitonin, and lactate dehydrogenase for the diagnosis of pancreatic necrosis
Test: 1 C-reactive protein (day 3) > 140 mg/L
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Rau 1998 32 5 7 26 0.82 [ 0.66, 0.92 ] 0.84 [ 0.66, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 2. C-reactive protein (day not stated) > 200 mg/L.
Review: Serum C-reactive protein, procalcitonin, and lactate dehydrogenase for the diagnosis of pancreatic necrosis
Test: 2 C-reactive protein (day not stated) > 200 mg/L
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Alfonso 2003 22 33 3 99 0.88 [ 0.69, 0.97 ] 0.75 [ 0.67, 0.82 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 3. C-reactive protein (day not stated) > 279 mg/L.
Review: Serum C-reactive protein, procalcitonin, and lactate dehydrogenase for the diagnosis of pancreatic necrosis
Test: 3 C-reactive protein (day not stated) > 279 mg/L
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Alfonso 2003 18 15 7 117 0.72 [ 0.51, 0.88 ] 0.89 [ 0.82, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 4. Procalcitonin (day 1) > 0.5 ng/mL.
Review: Serum C-reactive protein, procalcitonin, and lactate dehydrogenase for the diagnosis of pancreatic necrosis
Test: 4 Procalcitonin (day 1) > 0.5 ng/mL
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bertsch 1997 6 3 2 4 0.75 [ 0.35, 0.97 ] 0.57 [ 0.18, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 5. Lactate dehydrogenase (day 5) > 290 U/L.
Review: Serum C-reactive protein, procalcitonin, and lactate dehydrogenase for the diagnosis of pancreatic necrosis
Test: 5 Lactate dehydrogenase (day 5) > 290 U/L
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Rau 1998 34 0 5 31 0.87 [ 0.73, 0.96 ] 1.00 [ 0.89, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. Acute pancreatitis classification
Mild acute pancreatitis Moderate acute pancreatitis Severe acute pancreatitis
• No local or systemic complications.
• No organ failure.
• Interstitial oedematous pancreatitis.
• Local or systemic complications
(peripancreatic fluid collection, pancreatic
pseudocyst, necrosis) may be present.
• Transient organ failure (up to 48 hrs)
may be present.
• May be interstitial oedematous
pancreatitis or necrotising pancreatitis.
• Necrotising pancreatitis may be
infected or sterile.
• Local or systemic complications may
be present.
• Persistent organ failure (> 48 hrs)
present.
• May be interstitial oedematous
pancreatitis or necrotising pancreatitis.
• Necrotising pancreatitis may be
infected or sterile.
Table 2. QUADAS-2 classification (acute necrotising pancreatitis)
Domain 1: Participant selection Patient sampling Adult participants with acute pancreatitis
and without organ failure
Was a consecutive or random sample of pa-
tients enrolled?
Yes: If a consecutive sample or a random
sample of participantswith acute pancreati-
tis and without organ failure was included
in the study.
No: If a consecutive sample or a random
sample of participants with acute pancre-
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Table 2. QUADAS-2 classification (acute necrotising pancreatitis) (Continued)
atitis and without organ failure was not in-
cluded in the study.
Unclear: If this information was not avail-
able.
Did the study avoid inappropriate exclu-
sions?
Yes: If all participants with acute pancreati-
tis andwithout organ failure were included.
No: If the study excluded participants
based on high or low probability of pancre-
atic necrosis (e.g. those with normal white
cell count were excluded).
Unclear: If this information was not avail-
able.
Could the selection of participants have in-
troduced bias?
Low risk of bias: If ’yes’ classification for
both of the above two questions
High risk of bias: If ’no’ classification for
either of the above two questions
Unclear risk of bias: If ’unclear’ classifica-
tion for either of the above two questions,
but without a ’no’ classification for either
of the above two questions
Participant characteristics and setting We recorded the following characteristics:
sample size, females, age, presentation (in-
clusion and exclusion criteria), and setting
(primary or secondary care and country)
Are there concerns that the included partic-
ipants and setting do not match the review
question?
Low concern: If the participant character-
istics and setting is classified as ’yes’
Unclear concern: If the participant charac-
teristics and setting is classified as ’unclear’
High concern: If the participant character-
istics and setting is classified as ’no’
Domain 2: Index test Index test(s) Serum C-reactive protein, procalcitonin,
lactate dehydrogenase
Were the index test results interpretedwith-
out knowledge of the results of the refer-
ence standard?
The index test would always be conducted,
though not interpreted before the reference
standard
Yes: If the index test is conducted and in-
terpreted without knowledge of the results
of the reference standard.
No: If the index test is interpreted with
knowledge of the results of the reference
standard.
Unclear: If it is not clear whether the index
test was interpreted without knowledge of
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Table 2. QUADAS-2 classification (acute necrotising pancreatitis) (Continued)
the results of the reference standard
If a threshold was used, was it prespecified? Yes: If a prespecified threshold was used.
No: If a prespecified threshold was not
used.
Unclear: If it was not clear whether the
threshold used was prespecified
Could the conduct or interpretation of the
index test have introduced bias?
Low risk of bias: If ’yes’ classification for
both of the above two questions
High risk of bias: If ’no’ classification for
either of the above two questions
Unclear risk of bias: If ’unclear’ classifica-
tion for either of the above two questions,
but without a ’no’ classification for either
of the above two questions
Are there concerns that the index test, its
conduct, or interpretation differ from the
review question?
Low concern: If the criteria for positive in-
dex test were clearly stated
High concern: If the criteria for positive
index test were not stated
Domain 3: Target condition and refer-
ence standard
Target condition and reference standard(s) Target condition: pancreatic or peripancre-
atic necrosis (infected or sterile)
While considered to be the gold standard
for confirming necrosis, biopsy may not
have been performed in all participants due
to ethical concerns over performing an in-
vasive treatment (during which biopsy is
taken) in those without a diagnosis of pan-
creatic necrosis. As a result, study authors
may use radiological features of pancreatic
necrosis (an area of impairment enhance-
ment or non-enhancing area of pancreatic
parenchyma on CECT) or surgical features
of pancreatic necrosis during surgery (pres-
ence of necrotic tissue).However, this refer-
ence standard may miss some cases of pan-
creatic necrosis
In terms of ranking the reference standards,
we considered biopsy in all participants as
the best reference standard (although it is
unlikely to be performed in participants
with negative test for pancreatic necrosis)
followedby biopsy in participantswith pos-
itive test and radiological or surgical fea-
tures of pancreatic necrosis in participants
with negative test, and radiological tests or
surgical tests alone as the reference stan-
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Table 2. QUADAS-2 classification (acute necrotising pancreatitis) (Continued)
dard, in that order
Is the reference standard likely to correctly
classify the target condition?
Yes: If histological confirmation of pancre-
atic necrosiswas obtained in all participants
or at least all participants with positive test.
No: If the reference standardwasCECT(or
contrast enhanced MRI) in all participants
Unclear: If the reference standard was not
described adequately
Were the reference standard results inter-
preted without knowledge of the results of
the index test?
Yes: If the reference standard was inter-
preted without knowledge of the results of
the index test.
No: If the reference standard was inter-
preted with knowledge of the results of the
index test.
Unclear: If it was not clear if the reference
standard was interpreted without knowl-
edge of the results of the index test
Could the reference standard, its conduct,
or its interpretation have introduced bias?
Low risk of bias: If ’yes’ classification for
both of the above two questions
High risk of bias: If ’no’ classification for
either of the above two questions
Unclear risk of bias: If ’unclear’ classifica-
tion for either of the above two questions,
but without a ’no’ classification for either
of the above two questions
As anticipated, we assessed all studies as at
high risk of bias as they all used CECT or
surgery as the reference standard and were
therefore classified as ’no’ for the question
“Is the reference standard likely to correctly
classify the target condition?”
Are there concerns that the target condition
as defined by the reference standard does
not match the question?
As anticipated, considering the inclusion
criteria for this review,we classified all of the
included studies as ’low concern’, as they
all reported on pancreatic necrosis
Domain 4: Flow and timing Flow and timing Participants may have progression or re-
gression of pancreatic necrosis if there is a
long delay between index test and reference
standard. In addition, participants may re-
ceive treatment for organ failure if they
develop organ failure between the index
test and reference standard. We anticipated
that a radiological investigationwould have
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Table 2. QUADAS-2 classification (acute necrotising pancreatitis) (Continued)
been performedwithin 24 hours of diagno-
sis of organ failure. Pancreatic necrosis does
not resolve in 24 hours, and there will be
no alteration of the final diagnosis by the
treatment in participants with pancreatic
necrosis. People with oedematous pancre-
atitis and organ failure may develop pan-
creatic necrosis in the absence of appropri-
ate treatment. Consequently there is a pos-
sible interaction between inadequate treat-
ment and the final diagnosis. We havemin-
imised this misclassification error due to
the final diagnosis being altered by inap-
propriate treatment by choosing 24 hours
as an acceptable delay between index test
and reference standard
Was there an appropriate interval between
index test and reference standard?
Yes: If the time interval between index test
and reference standard was less than 24
hours.
No: If the time interval between index test
and reference standard was more than 24
hours.
Unclear: If the time interval between index
test and reference standard was unclear
Did all participants receive a reference stan-
dard?
Yes: If all participants received a reference
standard.
No: If some participants did not receive a
reference standard. Such studies were ex-
cluded.
Unclear: If it was not clear whether all
participants received a reference standard.
Such studies were excluded
As anticipated, we classified all studies in-
cluded in the review as ’yes’ for this item
Did all participants receive the same refer-
ence standard?
Yes: If all participants received the same ref-
erence standard.
No: If the reference standard participants
received varied.
Unclear: If this information was not clear.
Were all participants included in the anal-
ysis?
Yes: If all participants were included in the
analysis irrespective of whether the results
were interpretable.
No: If some participants were excluded
from the analysis because of uninter-
pretable results.
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Table 2. QUADAS-2 classification (acute necrotising pancreatitis) (Continued)
Unclear: If this information was not clear.
Could the patient flow have introduced
bias?
Low risk of bias: If ’yes’ classification for all
of the above four questions
High risk of bias: If ’no’ classification for
any of the above four questions
Unclear risk of bias: If ’unclear’ classifica-
tion for any of the above four questions,
but without a ’no’ classification for any of
the above four questions
CECT: contrast enhanced computed tomography
MRI: magnetic resonance imaging
A P P E N D I C E S
Appendix 1. Glossary of terms
Adipose: fat.
Aetiology: cause.
Autodigestion: breaking down of the same organ that secretes the substance.
Debridement: surgical removal of damaged, dead, or infected tissue; in this context, identical with necrosectomy.
Endoscopic: using an endoscope, a flexible tube with a light and camera attached to it to view the inner aspects of the food pipe,
stomach, and upper small intestine.
Epigastric: upper central abdomen.
Heterogeneity: differences between studies.
Histological: by examination of the tissue under a microscope.
Hyperamylasaemia: excess amylase in circulation.
Inflammation: localised physical condition in which part of the body becomes reddened, swollen, hot, and often painful, especially as
a reaction to injury or infection.
Interstitial: small, narrow spaces between tissues or parts of an organ.
Intraperitoneal: inside the abdominal cavity.
Laparoscopic: key-hole surgery.
Magnetic resonance cholangiopancreatography: medical imaging technique that uses magnetic resonance imaging (use of magnetic
field to differentiate between different structures) to visualise the biliary and pancreatic ducts in a non-invasive manner.
Necrosectomy: removal of dead tissue.
Necrosis: death and decomposition of living tissue usually caused by lack of blood supply, but can be the result of other pathological
insult.
Necrotising: presence of necrosis.
Oedema: swelling.
Oedematous: tissue with an excess of interstitial fluid.
Pancreatic ductal system: tubular system that transports the pancreatic juice secreted by the pancreatic cells to the small intestine.
Pancreatic pseudocysts: fluid collections in the pancreas or the tissues surrounding the pancreas, enclosed by a well-defined wall and
containing only fluid with little or no solid material.
Pancreatitis: inflammation of the pancreas.
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Parenchyma: functional parts of an organ.
Paucity: insufficient.
Percutaneous: through the skin.
Percutaneous drainage: drainage carried out by insertion of drain from the external surface of the body, usually guided by an ultrasound
or computed tomography (CT) scan.
Peripancreatic tissues: tissues surrounding the pancreas.
Radiating to the back: pain in front going to the back (in this context).
Retroperitoneal: behind the abdominal cavity.
Sphincterotomy: partial division of the sphincter of Oddi, a circular band of muscle at the junction of the biliary tree (tubes that
conduct bile from the liver to the small intestine) and pancreatic duct (tubes that conduct pancreatic juice into the second part of the
duodenum).
Transabdominal: through the abdominal cavity.
Transluminal: through the lumen (inner cavity of a tubular structure).
Transperitoneal: through the abdominal cavity.
Ultrasonography: using high-frequency sound to view internal structures of the body (in this context).
Appendix 2. MEDLINE search strategy
1. Pancreatitis, Acute Necrotizing/
2. Pancreatitis/et
3. Pancreas/ab, pa, pp
4. (acute adj3 pancrea*).mp.
5. (necro* adj3 pancrea*).mp.
6. (inflam* adj3 pancrea*).mp.
7. ((interstitial or edema* or oedema*) adj2 pancrea*).mp.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. exp Amylases/ or exp Lipase/ or exp Trypsinogen/
10. (amylase or lipase or trypsinogen or hyperamylasaemia or hyperamylasemia).mp.
11. exp C-Reactive Protein/
12. (“c-reactive protein” or “c reactive protein” or CRP).mp.
13. procalcitonin.mp.
14. exp L-Lactate Dehydrogenase/
15. (“lactate dehydrogenase” or LDH).mp.
16. 9 or 10 or 11 or 12 or 13 or 14 or 15
17. 8 and 16
Appendix 3. Embase search strategy
1. acute hemorrhagic pancreatitis/
2. Pancreatitis/et
3. acute pancreatitis/
4. (acute adj3 pancrea*).mp.
5. (necro* adj3 pancrea*).mp.
6. (inflam* adj3 pancrea*).mp.
7. ((interstitial or edema* or oedema*) adj2 pancrea*).mp.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. exp amylase/
10. exp triacylglycerol lipase/
11. exp trypsinogen/
12. (amylase or lipase or trypsinogen or hyperamylasaemia or hyperamylasemia).mp.
13. exp C reactive protein/
14. (“c-reactive protein” or “c reactive protein” or CRP).mp.
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15. exp procalcitonin/
16. procalcitonin.mp.
17. exp lactate dehydrogenase/
18. (“lactate dehydrogenase” or LDH).mp.
19. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
20. 8 and 19
Appendix 4. Science Citation Index and Conference Proceedings Citation Index-Science search
strategy
# 1 TS=((acute or necro* or inflam* or interstitial or edema* or oedema*) near/3 pancrea*)
# 2 TS=(amylase or lipase or trypsinogen or hyperamylasaemia or hyperamylasemia or “c-reactive protein” or “c reactive protein” or
CRP or procalcitonin or “lactate dehydrogenase” or LDH)
# 3 #2 AND #1
Appendix 5. National Institute for Health Research - HTA and DARE search strategy
acute pancreatitis
Appendix 6. Zetoc search strategy
Each of the following lines will be searched separately. since the Boolean operator ’or’ is not available for searching Zetoc database.
1. acute pancreatitis amylase
2. acute pancreatitis lipase
3. acute pancreatitis trypsinogen
4. acute pancreatitis hyperamylasaemia
5. acute pancreatitis hyperamylasemia
6. acute pancreatitis “c-reactive protein”
7. acute pancreatitis “c reactive protein”
8. acute pancreatitis CRP
9. acute pancreatitis procalcitonin
10. acute pancreatitis “lactate dehydrogenase”
11. acute pancreatitis LDH
Appendix 7. WHO ICTRP search strategy
Title: (amylase or lipase or trypsinogen or hyperamylasaemia or hyperamylasemia or “c-reactive protein” or “c reactive protein” or CRP
or procalcitonin or “lactate dehydrogenase” or LDH)
Condition: acute pancreatitis
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Appendix 8. ClinicalTrials.gov search strategy
amylase OR lipase OR trypsinogen OR hyperamylasaemia OR hyperamylasemia OR “c-reactive protein” OR “c reactive protein” OR
CRP OR procalcitonin OR “lactate dehydrogenase” OR LDH | acute pancreatitis
C O N T R I B U T I O N S O F A U T H O R S
Oluyemi Komolafe wrote the first draft of the review.
Kurinchi Selvan Gurusamy wrote the protocol and revised the review.
Stephen P Pereira and Brian R Davidson critically commented on the review.
D E C L A R A T I O N S O F I N T E R E S T
This report is independent research funded by the National Institute for Health Research (NIHR Cochrane Programme Grants, 13/
89/03 - Evidence-based diagnosis and management of upper digestive, hepato-biliary, and pancreatic disorders). The views expressed
in this publication are those of the author(s) and not necessarily those of the National Health Service, the NIHR, or the Department
of Health.
OK: none known.
SPP: none known.
BRD: none known.
KSG: none known.
S O U R C E S O F S U P P O R T
Internal sources
• University College London, UK.
External sources
• National Institute for Health Research, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
As per protocol, we accepted any of the following reference standards, used alone or in combination: radiological features of pancreatic
necrosis (contrast-enhanced computed tomography or magnetic resonance imaging) or histological confirmation of pancreatic necrosis.
In addition, we also included a combination of radiological features of pancreatic necrosis (contrast-enhanced computed tomography
or magnetic resonance imaging) and surgeon’s judgement of pancreatic necrosis during surgery, as we considered this equivalent to
radiologist judgement of the presence of pancreatic necrosis on radiology.
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